[go: up one dir, main page]

WO2007096764A3 - Bicyclic heteroaryl derivatives as cannabinoid receptor modulators - Google Patents

Bicyclic heteroaryl derivatives as cannabinoid receptor modulators Download PDF

Info

Publication number
WO2007096764A3
WO2007096764A3 PCT/IB2007/000459 IB2007000459W WO2007096764A3 WO 2007096764 A3 WO2007096764 A3 WO 2007096764A3 IB 2007000459 W IB2007000459 W IB 2007000459W WO 2007096764 A3 WO2007096764 A3 WO 2007096764A3
Authority
WO
WIPO (PCT)
Prior art keywords
cannabinoid
cannabinoid receptor
receptor modulators
disorders
bicyclic heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/000459
Other languages
French (fr)
Other versions
WO2007096764A2 (en
Inventor
Mrinalkanti Kundu
Neelima Khairatkar-Joshi
Suhas M Nadkarni
Rameshwar Madhavrao Pansare
Pallavi V Karnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ichnos Sciences SA
Original Assignee
Glenmark Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals SA filed Critical Glenmark Pharmaceuticals SA
Publication of WO2007096764A2 publication Critical patent/WO2007096764A2/en
Publication of WO2007096764A3 publication Critical patent/WO2007096764A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to; novel bicyclic derivatives of formula (I) : as cannabinoid receptor modulators, in particular cannabinoid 1 (CBl) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, obesity, smoking cessation, alcohol dependency, depression, and attention deficit hyperactivity disorder). Pharmaceutical compositions containing the described compounds, which can be used for the treatment of diseases, condition and/or disorders mediated by a cannabinoid receptor (such as CBl or CB2) are further provided.
PCT/IB2007/000459 2006-02-27 2007-02-26 Bicyclic heteroaryl derivatives as cannabinoid receptor modulators Ceased WO2007096764A2 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
IN275MU2006 2006-02-27
IN275/MUM/2006 2006-02-27
US78105506P 2006-03-10 2006-03-10
US60/781,055 2006-03-10
IN1146MU2006 2006-07-18
IN1146/MUM/2006 2006-07-18
US82147506P 2006-08-04 2006-08-04
US60/821,475 2006-08-04
IN2088MU2006 2006-12-20
IN2088/MUM/2006 2006-12-20

Publications (2)

Publication Number Publication Date
WO2007096764A2 WO2007096764A2 (en) 2007-08-30
WO2007096764A3 true WO2007096764A3 (en) 2008-07-10

Family

ID=38437745

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/000459 Ceased WO2007096764A2 (en) 2006-02-27 2007-02-26 Bicyclic heteroaryl derivatives as cannabinoid receptor modulators

Country Status (4)

Country Link
AR (1) AR059643A1 (en)
PE (1) PE20080114A1 (en)
TW (1) TW200745126A (en)
WO (1) WO2007096764A2 (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2660836A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
US7563797B2 (en) 2006-08-28 2009-07-21 Forest Laboratories Holding Limited Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands
DK2497470T3 (en) * 2006-11-22 2015-12-07 Incyte Holdings Corp Imidazotriaziner and imidazopyrimidines as kinase inhibitors
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
WO2009032754A2 (en) * 2007-08-31 2009-03-12 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
CN103936743B (en) 2008-05-21 2018-04-24 因西特控股公司 The salt of the fluoro- N- methyl -4- of 2- [7- (quinoline -6- ylmethyls) imidazo [1,2-b] [1,2,4] triazine -2- bases] benzamide and relative preparation method
RU2011123647A (en) 2008-11-10 2012-12-20 Вертекс Фармасьютикалз Инкорпорейтед COMPOUNDS USEFUL AS ATR KINASE INHIBITORS
NZ593104A (en) 2008-12-11 2012-11-30 Respivert Ltd P38 map kinase inhibitors
AU2009327357C1 (en) 2008-12-19 2017-02-02 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of ATR kinase
WO2010079241A1 (en) * 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Use of antagonists and/or inverse agonists of cb1 receptors for the preparation of drugs that increase motor neuron excitability
AU2010238361B2 (en) 2009-04-16 2015-08-06 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Imidazopyrazines for use as kinase inhibitors
GB0921730D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Method of treatment
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
AU2011269788B2 (en) 2010-02-03 2015-12-10 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazines as c-Met inhibitors
JP2013529200A (en) 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Compounds useful as ATR kinase inhibitors
EP2569289A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
WO2011143399A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
KR20130066633A (en) 2010-05-12 2013-06-20 버텍스 파마슈티칼스 인코포레이티드 Compounds useful as inhibitors of atr kinase
MX2012013082A (en) 2010-05-12 2013-05-09 Vertex Pharma 2 -aminopyridine derivatives useful as inhibitors of atr kinase.
EP2569287B1 (en) 2010-05-12 2014-07-09 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
MX2013000103A (en) 2010-06-23 2013-06-13 Vertex Pharma Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase.
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683700B1 (en) 2011-03-08 2015-02-18 Sanofi Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
KR101326557B1 (en) * 2011-03-31 2013-11-08 주식회사종근당 Benzamide derivatives as cannabinoid cb1 receptor antagonists
CA2832100A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
EP2723746A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2012178124A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CA3124539A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013049722A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN103957917A (en) 2011-09-30 2014-07-30 沃泰克斯药物股份有限公司 Treatment of pancreatic cancer and non-small cell lung cancer with ATR inhibitors
EP2751088B1 (en) 2011-09-30 2016-04-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776420A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776429A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2802586B1 (en) 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted imidazopyrazines as akt kinase inhibitors
US20140044802A1 (en) 2012-04-05 2014-02-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
EP2904406B1 (en) 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
EP2909202A1 (en) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
TWI600654B (en) 2012-11-19 2017-10-01 艾姆公司 Compounds and compositions for the treatment of parasitic diseases
RS64234B1 (en) 2012-12-07 2023-06-30 Vertex Pharma PYRAZOLO[1,5-A]PYRIMIDINES USEFUL AS ATR KINASE INHIBITORS FOR THE TREATMENT OF CANCER
CN103012284A (en) * 2012-12-26 2013-04-03 无锡捷化医药科技有限公司 Preparation method of 2-amino-5-bromopyrimidine compound
CA2897279C (en) 2013-01-23 2020-12-29 Astrazeneca Ab Aminopyrazine derivatives and pharmaceutical compositions thereof for use in the treatment of cancer
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SI3077397T1 (en) 2013-12-06 2020-02-28 Vertex Pharmaceuticals Inc. 2-amino-6-fluoro-n-(5-fluoro-pyridin-3-yl)pyrazolo(1,5-a)pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
GB201321736D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
SG11201610197XA (en) 2014-06-05 2017-01-27 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
NZ727399A (en) 2014-06-17 2022-07-29 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
HK1258570A1 (en) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. Method for treating cancer using a combination of dna damaging agents and atr inhibitors
TW201718581A (en) 2015-10-19 2017-06-01 英塞特公司 Heterocyclic compounds as immunomodulators
LT3377488T (en) 2015-11-19 2023-01-10 Incyte Corporation HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
US20170174679A1 (en) 2015-12-22 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
MA44860A (en) 2016-05-06 2019-03-13 Incyte Holdings Corp HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060256T2 (en) 2016-06-20 2023-02-28 Incyte Corp Heterocyclic compounds as immunomodulators
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018022865A1 (en) 2016-07-28 2018-02-01 Promega Corporation Coelenterazine analogues
CN106317059B (en) * 2016-08-19 2018-10-12 成都理工大学 A kind of 2 (CB2) agonist of Cannabined receptor
CN106317043B (en) * 2016-08-19 2018-11-02 成都理工大学 A kind of 2 agonist of Cannabined receptor
ES2941716T3 (en) 2016-08-29 2023-05-25 Incyte Corp Heterocyclic compounds as immunomodulators
WO2018119266A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
CN116115764A (en) 2016-12-22 2023-05-16 因赛特公司 Tetrahydroimidazo[4,5-C]pyridine derivatives as PD-L1 internalization inducers
JP7303108B2 (en) 2016-12-22 2023-07-04 インサイト・コーポレイション Bicyclic heteroaromatic compounds as immunomodulators
ES3030010T3 (en) 2018-03-30 2025-06-26 Incyte Corp Heterocyclic compounds as immunomodulators
BR112020022936A2 (en) 2018-05-11 2021-02-02 Incyte Corporation tetrahydro-imidazo [4,5-c] pyridine derivatives as pd-l1 immunomodulators
GB201811695D0 (en) 2018-07-17 2018-08-29 Salvensis Compounds for use in the treatment of fascioliasis
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
IL291471B2 (en) 2019-09-30 2025-04-01 Incyte Corp Pyrido[3,2-d]pyrimidine compounds as immunomodulators
JP2023500395A (en) 2019-11-11 2023-01-05 インサイト・コーポレイション Salts and Crystal Forms of PD-1/PD-L1 Inhibitors
TW202233616A (en) 2020-11-06 2022-09-01 美商英塞特公司 Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US20240101563A1 (en) * 2022-07-28 2024-03-28 Ac Immune Sa Novel compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455924A (en) * 1967-02-08 1969-07-15 Upjohn Co Dianisylimidazoles
WO2000008024A1 (en) * 1998-08-03 2000-02-17 Laboratorios S.A.L.V.A.T., S.A. Substituted imidazo[1,2a]azines as selective inhibotors of cox-2
JP2001043978A (en) * 1999-07-29 2001-02-16 Mitsui Chemicals Inc Organic electroluminescent element
US20030114495A1 (en) * 2001-07-20 2003-06-19 Finke Paul E. Substituted imidazoles as cannabinoid receptor modulators
WO2005014598A1 (en) * 2003-07-30 2005-02-17 Laboratorios S.A.L.V.A.T., S.A. Substituted imidazopyrimidines for the prevention and treatment of cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455924A (en) * 1967-02-08 1969-07-15 Upjohn Co Dianisylimidazoles
WO2000008024A1 (en) * 1998-08-03 2000-02-17 Laboratorios S.A.L.V.A.T., S.A. Substituted imidazo[1,2a]azines as selective inhibotors of cox-2
EP1104762A1 (en) * 1998-08-03 2001-06-06 Laboratorios S.A.L.V.A.T., S.A. Substituted imidazo 1,2a]azines as selective inhibotors of cox-2
JP2001043978A (en) * 1999-07-29 2001-02-16 Mitsui Chemicals Inc Organic electroluminescent element
US20030114495A1 (en) * 2001-07-20 2003-06-19 Finke Paul E. Substituted imidazoles as cannabinoid receptor modulators
WO2005014598A1 (en) * 2003-07-30 2005-02-17 Laboratorios S.A.L.V.A.T., S.A. Substituted imidazopyrimidines for the prevention and treatment of cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
C. ALMANSA ET AL, J. MED. CHEM., vol. 44, no. 3, 2001, pages 350 - 361, XP002308586 *
D.S. ERMOLAT'EV ET AL, J. COMB. CHEM., vol. 8, no. 5, 2006, pages 659 - 663, XP002457679 *
DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002457527, retrieved from STN Database accession no. 1999:719587 *
DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002457548, retrieved from STN Database accession no. 2001:117416 *
DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002457613, retrieved from STN Database accession no. 2004:23182 *
N.N. KOLOS ET AL, CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 39, no. 66, 2003, pages 771 - 775 *
S.C. BELL ET AL, J. AM. CHEM. SOC., vol. 82, 1960, pages 1469 - 1471, XP002308585 *
T. KURIHARA ET AL, CHEM. PHARM. BULL., vol. 30, no. 4, 1982, pages 1289 - 1299, XP008085632 *
V.G. KRUGLENKO, CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 35, no. 3, 1999, pages 374 - 375 *

Also Published As

Publication number Publication date
PE20080114A1 (en) 2008-04-16
AR059643A1 (en) 2008-04-16
TW200745126A (en) 2007-12-16
WO2007096764A2 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
WO2007096764A3 (en) Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
WO2006129178A8 (en) Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
WO2009010455A3 (en) Pyrazole derivatives as modulators of metabotropic glutamate receptors
AU2003276028A1 (en) Pyridine derivatives as cb2 receptor modulators
WO2009010871A3 (en) Pyrazole derivatives as antagonists of adenosine a3 receptor
WO2012009009A3 (en) Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
WO2008011363A3 (en) Quercetin-containing compositions
WO2008097428A3 (en) Compounds and compositions as modulators of gpr119 activity
WO2005082089A3 (en) Immunosuppressant compounds and compositions
WO2008132139A3 (en) New heterocyclic derivatives useful for the treatment of cns disorders
MX2009003981A (en) Calcium receptor modulating agents.
WO2007076070A3 (en) Modulators of muscarinic receptors
WO2006004741A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2007120655A3 (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
NO20076638L (en) New 8-sulfonylamino-3-amino-substituted chroman or tetrahydronaphthalene derivatives modulating the 5HT6 receptor
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2005030188A3 (en) Phenyl-piperazine derivatives as modulators of muscarinic receptors
WO2009051718A3 (en) Calcium receptor modulating agents
WO2008005908A3 (en) Pyridoimidazole derivatives
WO2008034142A3 (en) Synthesis, methods of using, and compositions of cycloalkylmethylamines
WO2006004684A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2008053341A3 (en) Bridged bicyclic indazoles as cannabinoid receptor ligands
WO2007120688A3 (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
WO2006105035A3 (en) Muscarinic modulators
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07713068

Country of ref document: EP

Kind code of ref document: A2